Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06276491

Public ClinicalTrials.gov record NCT06276491. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

Study identification

NCT ID: NCT06276491
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Xencor, Inc.; Industry
Enrollment: 282 participants

Conditions and interventions

Conditions

Interventions

XmAb541 Biological

Biological

Eligibility (public fields only)

Age range: 15 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 3, 2024
Primary completion: Nov 30, 2027
Completion: Nov 30, 2028
Last update posted: Aug 24, 2026

2024 – 2028

United States locations

U.S. sites: 17
U.S. states: 14
U.S. cities: 17

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
Stanford	Palo Alto	California	94304	Recruiting
University of California	San Francisco	California	94158	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Winship Cancer Institute, Emory University	Atlanta	Georgia	30322	Recruiting
University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
Indiana University Melvin and Bren Simon Comprehensive Cancer Center	Indianapolis	Indiana	46202	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
University of Minnesota	Minneapolis	Minnesota	55455	Recruiting
The John Theruer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Montefiore Einstein Comprehensive Cancer Center	The Bronx	New York	10461	Recruiting
The Ohio State University	Columbus	Ohio	43210	Recruiting
OU Health Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
University of Virginia	Charlottesville	Virginia	22903	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06276491, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 24, 2026 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06276491 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →